Century Gets Nod for 1st Allogeneic Cell Therapy Candidate to Overcome Major Pathways of Host vs Graft

 – Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA –

– First cell product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch –

– Phase 1 ELiPSE-1 trial evaluating CNTY-101 in relapsed or refractory CD19 positive B-cell malignancies anticipated to begin in 2H22 –

https://finance.yahoo.com/news/century-therapeutics-receives-study-may-113000642.html